iOmx Therapeutics AG

© iOmx Therapeutics AG

iOmx Therapeutics is aclinical-stage company that harnessesdeep tumor and myeloid biology insights, along with its proprietary iOTargTMtarget screening platform, to generatenovel treatments for the most prevalentsolid tumor indications. The companyis translating unexplored immune evasion biology into a growing pipeline ofbiomarker-enabled drug programs. Focused on developing drugs with singleagent activity, iOmx is creating potentialnew backbone therapies in a modality-open fashion.

The lead candidate OMX-0407, a spectrum-selective SIK kinase inhibitor, is currently being investigated in a Phase I/Ibclinical study in patients with previouslytreated unresectable solid tumors. Firstefficacy data are expected in 2025. Otherpipeline programs are in earlier stagesof pre-clinical development, includingIOMX-0675, a cross-specific antibody, simultaneously targeting the immunosuppressive receptors LILRB1 & LILRB2.IOMX-0675 will enter clinical development in early 2025.

Founded in 2016 and based in Martinsried / Munich, the company traces itsscientific roots to the German CancerResearch Center. iOmx has raised over€100m and is backed by internationalventure capital investors, includingAthos, Sofinnova Partners, WellingtonPartners, MIG Capital and M Ventures.